Journey Medical Corp Asset Resilience Ratio
Journey Medical Corp asset resilience ratio. Journey Medical Corp (DERM) has an Asset Resilience Ratio of 64.93% as of September 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See DERM defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Journey Medical Corp (2014–2018)
Asset resilience ratio of Journey Medical Corp from 2014 to 2018. This chart shows how Journey Medical Corp's Asset Resilience Ratio has changed over time. Read Journey Medical Corp total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Journey Medical Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Journey Medical Corp (DERM) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $283.23 Million | 64.93% |
| Total Liquid Assets | $283.23 Million | 64.93% |
Asset Resilience Insights
- Very High Liquidity: Journey Medical Corp maintains exceptional liquid asset reserves at 64.93% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Journey Medical Corp Industry Peers by Asset Resilience Ratio
Compare Journey Medical Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Journey Medical Corp Asset Resilience Ratio by Year (2014–2018)
Journey Medical Corp asset resilience ratio by year from 2014 to 2018. The table below shows the annual Asset Resilience Ratio data for Journey Medical Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | 60.43% | $208.06 Million | $344.32 Million | +14.94pp |
| 2017-12-31 | 45.48% | $255.07 Million | $560.79 Million | -21.74pp |
| 2016-12-31 | 67.23% | $210.15 Million | $312.60 Million | +18.81pp |
| 2015-12-31 | 48.42% | $107.45 Million | $221.93 Million | +24.97pp |
| 2014-12-31 | 23.45% | $41.79 Million | $178.22 Million | -- |
About Journey Medical Corp
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat sev… Read more